Bio-Path Holdings, Inc (BPTH): Aggregate Business Value

The confirmed price history on the chart for Bio-Path Holdings (BPTH) is , illustrating the position of a biotech startup whose budget is funded through new share issuances due to a lack of commercial revenue. Bio-Path Holdings (BPTH) will only gain pricing power upon the creation of a unique method for blocking oncoproteins. Currently, the company is engaged in a patent race to develop RNA therapy, where success depends exclusively on the results of late-stage clinical trials.

Enterprise value determines the actual cost of acquiring a business by summing market capitalization and debt obligations minus cash and cash equivalents. By analyzing the total capitalization including debt, an investor assesses the financial stability of Bio-Path Holdings (BPTH), whose capital is critically dependent on costly research and FDA drug approvals for leukemia therapy.